by Mark Curtis | May 14, 2014
. Welcome to your RM deal review for the month of April. There were two notable acquisitions this past month. NeoStem entered into an agreement to acquire California Stem Cell, while Aastrom acquired Sanofi’s regenerative medicine business. Read on to find out more....
by Holly Wobma | May 13, 2014
> I think one of the most universally embraced ideas when people gather together and pontificate about how their relatives or colleagues turned out they way they did, is that ‘people are a product of their environment’. I’m not here to make a singular stand against...
by Lisa Willemse | May 9, 2014
> I said goodbye to a much beloved uncle this week. I suppose it’s inevitable that mortality, aging and how and when we share our feelings with those we love would be on my mind over the 16 hours of driving to and from the funeral. Also not surprising that...
by David Kent | May 6, 2014
> My last post introduced the large-scale publicly funded clinical trial called BAMI (the effect of intracoronary reinfusion of Bone marrow-derived mononuclear cells on all course mortality in Acute Myocardial Infarction). That post focused on the role of the...
by Stacey Johnson | May 2, 2014
. May is the month that students learn whether they’ve been accepted into medical programs at Canadian universities. Good luck kids! Good luck parents! This infographic, on the evolution of medicine, comes courtesy of BestMedicalDegrees.com, an independent online...
by Mark Curtis | Apr 30, 2014
. Of all the formidable challenges that a biotechnology company will stumble upon in its quest to commercialize, perhaps there is none more frustrating than a failure to get a product reimbursed by payers. After years of navigating the gauntlet of risk that is...
by Lisa Willemse | Apr 25, 2014
> Julia Pon is a MD/PhD student at the University of British Columbia with an interest in blood cancer. Like many before her, she noticed that the kind of information that is shared with cancer patients is different than what medical students are taught about the...
by Paul Krzyzanowski | Apr 22, 2014
> If you’ve stayed current with the STAP cell fiasco you know it’s been a wild ride. STAP cells, or Stimulus-Triggered Acquisition of Pluripotency cells, caught the imagination of many in late January through their sheer simplicity: You hit cells with a shock of...
by Roshan Yoganathan | Apr 17, 2014
Recently Revmedx, a pioneer in the biomaterial wound dressing field, made some waves with the commercialization of its product XStatTM . XStatTM received a lot of press because of its FDA approval for use against gunshot wounds and shrapnel-related injuries in the...
by David Kent | Apr 15, 2014
> In February this year, the biggest stem cell trial for heart attack patients was begun and will involve over 3000 patients from 11 different countries in Europe. The BAMI trial (the effect of intracoronary reinfusion of Bone marrow-derived mononuclear cells on...
Comments